Caribou Biosciences (CRBU) Non Operating Investment Income (2022 - 2024)
Caribou Biosciences (CRBU) posted quarterly Non Operating Investment Income of -$14000.0 for Q3 2024, down 250.0% year-over-year from $9333.3 in Q4 2023, and up 86.27% quarter-over-quarter from -$102000.0 in Q2 2024.
Caribou Biosciences (CRBU) Non Operating Investment Income (2022 - 2024) Analysis & Trends
Caribou Biosciences (CRBU) has reported Non Operating Investment Income for 3 consecutive years, with -$14000.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Non Operating Investment Income fell 250.0% year-over-year to -$14000.0; the TTM figure through Sep 2024 stood at -$125000.0 (down 119.3% YoY), while the FY2023 annual figure was -$6000.0, up 95.49% from the prior year.
- Non Operating Investment Income climbed to -$14000.0 in Q3 2024 per CRBU's latest filing, from -$102000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $31000.0 in Q3 2022 and bottomed at -$102000.0 in Q2 2024.
- Historically, Non Operating Investment Income has averaged -$25500.0 across 3 years, with a median of -$14500.0 in 2023.
- Annual changes were most pronounced in 2023 — Non Operating Investment Income soared 237.5% — and 2024, when it sank 563.64%.
- Caribou Biosciences' Non Operating Investment Income stood at -$60000.0 in 2022, then soared by 85.0% to -$9000.0 in 2023, then slumped by 55.56% to -$14000.0 in 2024.
- Business Quant data shows CRBU's Non Operating Investment Income at -$14000.0 in Q3 2024, -$102000.0 in Q2 2024, and -$9000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -14,000.00 |
| Sep 30, 2024 | -14,000.00 |
| Jun 30, 2024 | -102,000.00 |
| Jun 30, 2024 | -102,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Jun 30, 2023 | 22,000.00 |
| Mar 31, 2023 | -15,000.00 |
| Mar 31, 2023 | -15,000.00 |
| Dec 31, 2022 | -60,000.00 |
| Dec 31, 2022 | -60,000.00 |
| Sep 30, 2022 | 31,000.00 |
| Sep 30, 2022 | 31,000.00 |
| Jun 30, 2022 | -16,000.00 |
| Jun 30, 2022 | -16,000.00 |
| Mar 31, 2022 | -88,000.00 |
| Mar 31, 2022 | -88,000.00 |